表紙
市場調查報告書
商品編碼
1032617

咳嗽藥市場:按產品類型、年齡組、分銷渠道:全球機會分析和行業預測,2021-2030

Cough Remedies Market by Product Type, Age Group, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2030

出版日期: | 出版商: Allied Market Research | 英文 234 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

2020 年全球咳嗽藥市場達到 70.845 億美元。

預計從 2021 年到 2030 年,市場將以 3.4% 的複合年增長率增長,到 2030 年達到 9,911,200,000 美元。

咳嗽是對喉嚨和呼吸道刺激的反應。持續數週的咳嗽或帶有變色或帶血的粘液的咳嗽表明您需要去看醫生。此外,咳嗽還會引起失眠、頭暈昏厥、頭痛、尿失禁、嘔吐,甚至肋骨骨折。咳嗽的治療包括咳嗽藥,它使用溶解粘液和抑制咳嗽反射的藥物。這種類型的治療有助於在短期內減少咳嗽的次數和強度。

全球咳嗽市場的增長主要是由於COPD(慢性阻塞性肺病)、哮喘、慢性咳嗽和肺炎等呼吸系統疾病的增加。預計社區獲得性肺炎的增加也將在預測期內推動行業增長。此外,越來越多的產品在FDA(美國食品藥品監督管理局)批准後上市的案例預計將有助於該行業的利潤增長。此外,咳嗽藥物研發臨床試驗的激增可能會在未來幾年推動行業增長。然而,對咳嗽藥的嚴格規定一直是市場增長的障礙。越來越多的老年人因免疫力下降而容易咳嗽和感冒,這推動了咳嗽藥市場的增長。此外,引起過敏反應和誘發咳嗽的汽車污染的增加正在推動咳嗽藥市場的需求。

本報告調查了咳嗽藥市場,並提供了市場概況,以及按產品類型、年齡組、分銷渠道、地區和進入市場的公司概況劃分的趨勢。

目錄

第 1 章介紹

第 2 章執行摘要

第 3 章市場情況

  • 市場定義和範圍
  • 主要調查結果
    • 主要投資領域
    • 主要成功策略
  • 波特五力分析
  • 2020 年頂級公司定位
  • 市場動態
    • 促進因素
      • 呼吸道疾病患病率增加
      • 免疫力較弱的老年人口快速增加
      • 主要參與者採用的戰略舉措
    • 抑制因素
      • 對慢性咳嗽的治療有嚴格規定
    • 市場機會
      • 一種攻擊呼吸系統的新病毒的爆發
    • 影響分析
  • COVID-19對咳嗽藥市場的影響分析

第 4 章止咳藥市場:按產品類型

  • 概述
    • 市場規模和預測
  • 祛痰劑
    • 市場規模和預測
    • 市場分析:按國家/地區
  • 支氣管擴張劑和止咳藥
    • 市場規模和預測
    • 市場分析:按國家/地區
  • 減充血劑
    • 市場規模和預測
    • 市場分析:按國家/地區
  • 抗生素
    • 市場規模和預測
    • 市場分析:按國家/地區

第 5 章咳嗽市場:按年齡組

  • 概述
    • 市場規模和預測
  • 兒童
    • 市場規模和預測
    • 市場分析:按國家/地區
  • 成人
    • 市場規模和預測
    • 市場分析:按國家/地區

第 6 章咳嗽市場:按分銷渠道

  • 概述
    • 市場規模和預測
  • 零售藥店
    • 市場規模和預測
    • 市場分析:按國家/地區
    • 市場規模和預測:按年齡組
  • 院內藥房
    • 市場規模和預測
    • 市場分析:按國家/地區
    • 市場規模和預測:按年齡組
  • 網上藥店
    • 市場規模和預測
    • 市場分析:按國家/地區
    • 市場規模和預測:按年齡組

第 7 章咳嗽市場:按地區

  • 概述
    • 市場規模和預測
  • 北美
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按國家/地區
      • 美國
      • 加拿大
      • 墨西哥
    • 北美市場規模和預測:按產品類型
    • 北美市場規模和預測:按年齡組
    • 北美市場規模和預測:按分銷渠道
  • 歐洲
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按國家/地區
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他
    • 歐洲市場規模和預測:按產品類型
    • 歐洲市場規模和預測:按年齡組
    • 歐洲市場規模和預測:按分銷渠道
  • 亞太地區
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按國家/地區
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 其他亞太地區
    • 亞太市場規模和預測:按產品類型
    • 亞太市場規模和預測:按年齡組
    • 亞太市場規模和預測:按分銷渠道
  • 拉美亞
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按國家/地區
      • 巴西
      • 沙特阿拉伯
      • 南非
      • 其他
    • LAMEA 市場規模和預測:按產品類型
    • LAMEA 市場規模和預測:按年齡組
    • LAMEA 市場規模和預測:按分銷渠道

第 8 章公司簡介

  • ASTRAZENECA PLC
  • BAYER AG
  • GLAXOSMITHKLINE PLC
  • JOHNSON & JOHNSON
  • Novartis International AG
  • PFIZER, INC.
  • PRESTIGE BRANDS INC.
  • PROCTER & GAMBLE(P&G)
  • Reckitt Benckiser Group plc.
  • SUN PHARMACEUTICALS INDUSTRIES LIMITED
目錄
Product Code: A03251

The global Cough Remedies market was valued at $7084.5 million in 2020, and is projected to reach $9911.2 million by 2030, registering a CAGR of 3.4% from 2021 to 2030.

Cough is a response to irritation caused to throat or airways. A cough that persists for several weeks or one that brings up discolored or bloody mucus indicates a condition that needs medical attention. Furthermore, cough can cause sleeplessness, dizziness or fainting, headaches, urinary incontinence, vomiting, and even broken ribs. Cough remedies may include, cough-suppressant therapy that incorporates the use of pharmacologic agents with mucolytic effects and inhibitory effects on the cough reflex itself. This type of helps to reduce frequency and intensity of coughing on a short-term basis.

Growth of the global cough remedies market is majorly driven by rise in incidences of respiratory diseases such as COPD, asthma, chronic cough, and pneumonia. In addition, increase in prevalence community-acquired pneumonia is expected to propel the industry growth during the forecast period. Furthermore, increase in product launches after FDA approval is expected to help the industry gain maximum revenue. In addition, surge in clinical trials for R&D for development of cough remedies is projected to help the industry grow in the next few years. However, implementation of stringent regulations for cough remedies hinders the market growth. Surge in geriatric population who are more prone to cough and cold due to weakened immune system, which propels the cough remedies market growth. Furthermore, increase in vehicle pollution, which causes allergic reaction and triggers cough, which propels demand for the cough remedies market.

The global cough remedies market is segmented into product type, age group, distribution channel, and region. On the basis of product type, the market is categorized into expectorants, antihistamines, bronchodilators, decongestants, and antibiotics. Depending on age group, it is segregated into pediatric and adult. By distribution channel, it is classified into retail pharmacy, hospital pharmacy, and online pharmacy. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

By product type, the expectorants segment is anticipated to garner highest revenue during the forecast period, owing to surge in incidences of respiratory diseases and surge in demand for drugs from individuals suffering from respiratory disorders. However, the antibiotics segment is expected to gain significant share during the forecast period.

By age group, the geriatric segment is anticipated to gain highest revenue segment during the forecast period, owing to rise in geriatric population worldwide. Furthermore, susceptibility to develop age-associated diseases promotes the market growth. In addition, the pediatric segment is expected to help the market growth, owing to surge in incidences of chronic cough among pediatrics.

By distribution channel, the hospital pharmacy segment is anticipated to garner highest revenue during the forecast period. In addition, the retail pharmacy segment is expected to propel growth of the cough remedies market during the forecast period.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of factors that drive and restrain growth of the market is provided.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Product Type

  • Expectorants
  • Antihistamines
  • Bronchodilators
  • Decongestants
  • Antibiotics

By Age Group

  • Pediatric
  • Adult

By Distribution Channel

  • Retail Pharmacy
  • Pediatric
  • Adult
  • Hospital Pharmacy
  • Pediatric
  • Adult
  • Online Pharmacy
  • Pediatric
  • Adult

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

  • Astrazeneca PLC (Astrazeneca)
  • Bayer Ag
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novartis AG
  • Pfizer, Inc.
  • Prestige Brands, Inc.
  • Procter & Gamble
  • Reckitt Benckiser Group PLC.
  • Sun Pharmaceuticals Industries Limited

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key Benefits for Stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five force analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Increase in prevalence of respiratory diseases
      • 3.5.1.2.Upsurge in geriatric population with weaker immune systems
      • 3.5.1.3.Surge in strategic moves adopted by major players
    • 3.5.2.Restraint
      • 3.5.2.1.Stringent regulations for treatment of chronic cough
    • 3.5.3.Opportunity
      • 3.5.3.1.Outbreak of novel viruses attacking respiratory system
    • 3.5.4.Impact analysis
  • 3.6.COVID-19 Impact analysis on the cough remedies market

CHAPTER 4:COUGH REMEDIES MARKET, BY PRODUCT TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Expectorants
    • 4.2.1.Market size and forecast
    • 4.2.2.Market analysis, by country
  • 4.3.Bronchodilators and cough suppressants
    • 4.3.1.Market size and forecast
    • 4.3.2.Market analysis, by country
  • 4.4.Decongestants
    • 4.4.1.Market size and forecast
    • 4.4.2.Market analysis, by country
  • 4.5.Antibiotics
    • 4.5.1.Market size and forecast
    • 4.5.2.Market analysis, by country

CHAPTER 5:COUGH REMEDIES MARKET, BY AGE GROUP

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Pediatric
    • 5.2.1.Market size and forecast
    • 5.2.2.Market analysis, by country
  • 5.3.Adult
    • 5.3.1.Market size and forecast
    • 5.3.2.Market analysis, by country

CHAPTER 6:COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Retail Pharmacy
    • 6.2.1.Market size and forecast
    • 6.2.2.Market analysis, by country
    • 6.2.3.Market size and forecast, by route of age group
  • 6.3.Hospital pharmacy
    • 6.3.1.Market size and forecast
    • 6.3.2.Market analysis, by country
    • 6.3.3.Market size and forecast, by route of age group
  • 6.4.Online pharmacy
    • 6.4.1.Market size and forecast
    • 6.4.2.Market analysis, by country
    • 6.4.3.Market size and forecast, by route of age group

CHAPTER 7:COUGH REMEDIES MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.Market size and forecast, by country
      • 7.2.2.1.U.S.
      • 7.2.2.1.1.U.S. cough remedies market, by product type
      • 7.2.2.1.2.U.S. cough remedies market, by age group
      • 7.2.2.1.3.U.S. cough remedies market, by distribution channel
      • 7.2.2.2.Canada
      • 7.2.2.2.1.Canada cough remedies market, by product type
      • 7.2.2.2.2.Canada cough remedies market, by age group
      • 7.2.2.2.3.Canada cough remedies market, by distribution channel
      • 7.2.2.3.Mexico
      • 7.2.2.3.1.Mexico cough remedies market, by product type
      • 7.2.2.3.2.Mexico cough remedies market, by age group
      • 7.2.2.3.3.Mexico cough remedies market, by distribution channel
    • 7.2.3.North America market size and forecast, by product type
    • 7.2.4.North America market size and forecast, by age group
    • 7.2.5.North America market size and forecast, by product type
    • 7.2.6.North America market size and forecast, by distribution channel
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Market size and forecast, by country
      • 7.3.2.1.Germany
      • 7.3.2.1.1.Germany cough remedies market, by product type
      • 7.3.2.1.2.Germany cough remedies market, by age group
      • 7.3.2.1.3.Germany cough remedies market, by distribution channel
      • 7.3.2.2.France
      • 7.3.2.2.1.France cough remedies market, by product type
      • 7.3.2.2.2.France cough remedies market, by age group
      • 7.3.2.2.3.France cough remedies market, by distribution channel
      • 7.3.2.3.UK
      • 7.3.2.3.1.UK cough remedies market, by product type
      • 7.3.2.3.2.UK cough remedies market, by age group
      • 7.3.2.3.3.UK cough remedies market, by distribution channel
      • 7.3.2.4.Italy
      • 7.3.2.4.1.Italy cough remedies market, by product type
      • 7.3.2.4.2.Italy cough remedies market, by age group
      • 7.3.2.4.3.Italy cough remedies market, by distribution channel
      • 7.3.2.5.Spain
      • 7.3.2.5.1.Spain cough remedies market, by product type
      • 7.3.2.5.2.Spain cough remedies market, by age group
      • 7.3.2.5.3.Spain cough remedies market, by distribution channel
      • 7.3.2.6.Rest of Europe
      • 7.3.2.6.1.Rest of Europe cough remedies market, by product type
      • 7.3.2.6.2.Rest of Europe cough remedies market, by age group
      • 7.3.2.6.3.Rest of Europe cough remedies market, by distribution channel
    • 7.3.4.Europe market size and forecast, by product type
    • 7.3.5.Europe market size and forecast, by age group
    • 7.3.6.Europe market size and forecast, by distribution channel
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Market size and forecast, by country
      • 7.4.2.1.Japan
      • 7.4.2.1.1.Japan cough remedies market, by product type
      • 7.4.2.1.2.Japan cough remedies market, by age group
      • 7.4.2.1.3.Japan cough remedies market, by distribution channel
      • 7.4.2.2.China
      • 7.4.2.2.1.China cough remedies market, by product type
      • 7.4.2.2.2.China cough remedies market, by age group
      • 7.4.2.2.3.China cough remedies market, by distribution channel
      • 7.4.2.3.Australia
      • 7.4.2.3.1.Australia cough remedies market, by product type

Source: Primary & Secondary Research and AMR Analysis

      • 7.4.2.3.2.Australia cough remedies market, by age group
      • 7.4.2.3.3.Australia cough remedies market, by distribution channel
      • 7.4.2.4.India
      • 7.4.2.4.1.India cough remedies market, by product type
      • 7.4.2.4.2.India cough remedies market, by age group
      • 7.4.2.4.3.India cough remedies market, by distribution channel
      • 7.4.2.5.Rest of Asia-Pacific
      • 7.4.2.5.1.Rest of Asia-Pacific cough remedies market, by product type
      • 7.4.2.5.2.Rest of Asia-Pacific cough remedies market, by age group
      • 7.4.2.5.3.Rest of Asia-Pacific cough remedies market, by distribution channel
    • 7.4.3.Asia-Pacific market size and forecast, by product type
    • 7.4.4.Asia-Pacific market size and forecast, by age group
    • 7.4.5.Asia-Pacific market size and forecast, by distribution channel
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.Market size and forecast, by country
      • 7.5.2.1.Brazil
      • 7.5.2.1.1.Brazil cough remedies market, by product type

Source: Primary & Secondary Research and AMR Analysis

      • 7.5.2.1.2.Brazil cough remedies market, by age group
      • 7.5.2.1.3.Brazil cough remedies market, by distribution channel
      • 7.5.2.2.Saudi Arabia
      • 7.5.2.2.1.Saudi Arabia cough remedies market, by product type
      • 7.5.2.2.2.Saudi Arabia cough remedies market, by age group
      • 7.5.2.2.3.Saudi Arabia cough remedies market, by distribution channel
      • 7.5.2.3.South Africa
      • 7.5.2.3.1.South Africa cough remedies market, by product type
      • 7.5.2.3.2.South Africa cough remedies market, by age group
      • 7.5.2.3.3.South Africa cough remedies market, by distribution channel
      • 7.5.2.4.Rest of LAMEA
      • 7.5.2.4.1.Rest of LAMEA cough remedies market, by product type
      • 7.5.2.4.2.Rest of LAMEA cough remedies market, by age group
      • 7.5.2.4.3.Rest of LAMEA cough remedies market, by distribution channel
    • 7.5.4.LAMEA market size and forecast, by product type
    • 7.5.5.LAMEA market size and forecast, by age group
    • 7.5.6.LAMEA market size and forecast, by distribution channel

CHAPTER 8:COMPANY PROFILES

  • 8.1.ASTRAZENECA PLC
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
    • 8.1.6.Key strategic moves and developments
  • 8.2.BAYER AG
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
  • 8.3.GLAXOSMITHKLINE PLC
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
    • 8.3.6.Key strategic moves and developments
  • 8.4.JOHNSON & JOHNSON
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
  • 8.5.Novartis International AG
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
  • 8.6.PFIZER, INC.
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
  • 8.7.PRESTIGE BRANDS INC.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
  • 8.8.PROCTER & GAMBLE (P&G)
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
  • 8.9.Reckitt Benckiser Group plc.
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
  • 8.10.SUN PHARMACEUTICALS INDUSTRIES LIMITED
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance

LIST OF TABLES

  • TABLE 01.GLOBAL COUGH REMEDIES MARKET BY PRODUCT TYPE, 2020-2030, ($MILLION)
  • TABLE 02.COUGH REMEDIES MARKET FOR EXPECTORANTS MARKET BY REGION 2020-2030, ($MILLION)
  • TABLE 03.COUGH REMEDIES MARKET FOR BRONCHODILATORS AND COUGH SUPPRESSANTSMARKET BY REGION 2020-2030, ($MILLION)
  • TABLE 04.COUGH REMEDIES MARKET FOR DECONGESTANTS MARKET BY REGION 2020-2030, ($MILLION)
  • TABLE 05.COUGH REMEDIES MARKET FOR ANTIBIOTICS MARKET BY REGION 2020-2030, ($MILLION)
  • TABLE 06.COUGH REMEDIES MARKET BY AGE GROUP, 2020-2030, ($MILLION)
  • TABLE 07.COUGH REMEDIES MARKET FOR PEDIATRIC MARKET BY REGION, 2020-2030, ($MILLION)
  • TABLE 08.COUGH REMEDIES MARKET FOR ADULT, BY REGION 2020-2030, ($MILLION)
  • TABLE 09.COUGH REMEDIES MARKET BY DISTRIBUTION CHANNEL, 2020-2030, ($MILLION)
  • TABLE 10.COUGH REMEDIES MARKET FOR RETAIL PHARMACY BY DISTRIBUTION CHANNEL 2020-2030, ($MILLION)
  • TABLE 11.COUGH REMEDIES MARKET FOR RETAIL PHARMACY, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 12.COUGH REMEDIES MARKET FOR HOSPITAL PHARMACY BY DISTRIBUTION CHANNEL 2020-2030, ($MILLION)
  • TABLE 13.COUGH REMEDIES MARKET FOR HOSPITAL PHARMACY, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 14.COUGH REMEDIES MARKET FOR ONLINE PHARMACY BY DISTRIBUTION CHANNEL 2020-2030, ($MILLION)
  • TABLE 15.COUGH REMEDIES MARKET FOR HOSPITAL PHARMACY, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 16.COUGH REMEDIES MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 17.NORTH AMERICA COUGH REMEDIES MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 18.U.S. COUGH REMEDIES MARKET BY PRODUCT TYPE, 2020-2030, ($MILLION)
  • TABLE 19.U.S. COUGH REMEDIES MARKET BY AGE GROUP, 2020-2030, ($MILLION)
  • TABLE 20.U.S. COUGH REMEDIES MARKET BY DISTRIBUTION CHANNEL, 2020-2030, ($MILLION)
  • TABLE 21.CANADA COUGH REMEDIES MARKET BY PRODUCT TYPE, 2020-2030, ($MILLION)
  • TABLE 22.CANADA COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 23.CANADA COUGH REMEDIES MARKET BY DISTRIBUTION CHANNEL, 2020-2030, ($MILLION)
  • TABLE 24.MEXICO COUGH REMEDIES MARKET BY PRODUCT TYPE, 2020-2030, ($MILLION)
  • TABLE 25.MEXICO COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 26.MEXICO COUGH REMEDIES MARKET BY DISTRIBUTION CHANNEL, 2020-2030, ($MILLION)
  • TABLE 27.NORTH AMERICA COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 28.NORTH AMERICA COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 29.NORTH AMERICA COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 30.NORTH AMERICA COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 31.EUROPE COUGH REMEDIES MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 32.GERMANY COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 33.GERMANY COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 34.GERMANY COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 35.FRANCE COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 36.FRANCE COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 37.FRANCE COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 38.UK COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 39.UK COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 40.UK COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 41.ITALY COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 42.ITALY COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 43.ITALY COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 44.SPAIN COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 45.SPAIN COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 46.SPAIN COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 47.REST OF EUROPE COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 48.REST OF EUROPE COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 49.REST OF EUROPE COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 50.EUROPE COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 51.EUROPE COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 52.EUROPE COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 53.ASIA-PACIFIC COUGH REMEDIES MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 54.JAPAN COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 55.JAPAN COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 56.JAPAN COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 57.CHINA COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 58.CHINA COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 59.CHINA COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 60.AUSTRALIA COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 61.AUSTRALIA COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 62.AUSTRALIA COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 63.INDIA COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 64.INDIA COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 65.INDIA COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 66.REST OF ASIA-PACIFIC COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 67.REST OF ASIA-PACIFIC COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 68.REST OF ASIA-PACIFIC COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 69.ASIA-PACIFIC COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 70.ASIA-PACIFIC COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 71.ASIA-PACIFIC COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 72.LAMEA COUGH REMEDIES MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 73.BRAZIL COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 74.BRAZIL COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 75.BRAZIL COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 76.SAUDI ARABIA COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 77.SAUDI ARABIA COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 78.SAUDI ARABIA COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 79.SOUTH AFRICA COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 80.SOUTH AFRICA COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 81.SOUTH AFRICA COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 82.REST OF LAMEA COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 83.REST OF LAMEA COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 84.REST OF LAMEA COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 85.LAMEA COUGH REMEDIES MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 86.LAMEA COUGH REMEDIES MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
  • TABLE 87.LAMEA COUGH REMEDIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 88.ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 89.ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 90.ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 91.ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 92.BAYER: COMPANY SNAPSHOT
  • TABLE 93.BAYER: OPERATING SEGMENTS
  • TABLE 94.BAYER: PRODUCT PORTFOLIO
  • TABLE 95.GLAXOSMITHKLINE: COMPANY SNAPSHOT
  • TABLE 96.GLAXOSMITHKLINE: OPERATING SEGMENTS
  • TABLE 97.GLAXOSMITHKLINE: PRODUCT PORTFOLIO
  • TABLE 98.GLAXOSMITHKLINE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99.J&J: COMPANY SNAPSHOT
  • TABLE 100.J&J: OPERATING BUSINESS SEGMENTS
  • TABLE 101.J&J: PRODUCT PORTFOLIO
  • TABLE 102.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 103.NOVARTIS: OPERATING SEGMENT
  • TABLE 104.NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 105.PFIZER: COMPANY SNAPSHOT
  • TABLE 106.PFIZER: OPERATING SEGMENT
  • TABLE 107.PFIZER: PRODUCT TYPE PORTFOLIO
  • TABLE 108.PRESTIGE: COMPANY SNAPSHOT
  • TABLE 109.PRESTIGE: OPERATING SEGMENTS
  • TABLE 110.PRESTIGE: PRODUCT PORTFOLIO
  • TABLE 111.P&G: COMPANY SNAPSHOT
  • TABLE 112.P&G: OPERATING BUSINESS SEGMENTS
  • TABLE 113.P&G: PRODUCT PORTFOLIO
  • TABLE 114.RECKITT: COMPANY SNAPSHOT
  • TABLE 115.RECKITT: OPERATING BUSINESS SEGMENTS
  • TABLE 116.RECKITT: PRODUCT PORTFOLIO
  • TABLE 117.SUN PHARMA: COMPANY SNAPSHOT
  • TABLE 118.SUN PHARMA: OPERATING SEGMENT
  • TABLE 119.SUN PHARMA: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.COUGH REMEDIES MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
  • FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.HIGH BARGAINING POWER OF BUYERS
  • FIGURE 08.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 09.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 10.HIGH INTENSITY OF RIVALRY
  • FIGURE 11.TOP PLAYER POSITIONING, 2020
  • FIGURE 12.IMPACT ANALYSIS
  • FIGURE 13.COMPARATIVE ANALYSIS OF COUGH REMEDIES MARKET, FOR EXPECTORANTS, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 14.COMPARATIVE ANALYSIS OF COUGH REMEDIES MARKET, FOR BRONCHODILATORS AND COUGH SUPPRESSANTS, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 15.COMPARATIVE ANALYSIS OF COUGH REMEDIES MARKET, FOR DECONGESTANTS, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF COUGH REMEDIES MARKET, FOR ANTIBIOTICS, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 17.COMPARATIVE ANALYSIS OF COUGH REMEDIES MARKET, FOR PEDIATRIC, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 18.COMPARATIVE ANALYSIS OF COUGH REMEDIES MARKET, FOR ADULT, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 19.COMPARATIVE ANALYSIS OF COUGH REMEDIES MARKET, FOR RETAIL PHARMACY, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 20.COMPARATIVE ANALYSIS OF COUGH REMEDIES MARKET, FOR HOSPITAL PHARMACY, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 21.COMPARATIVE ANALYSIS OF COUGH REMEDIES MARKET, FOR ONLINE PHARMACY, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 22.ASTRAZENECA: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 23.ASTRAZENECA: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 24.BAYER: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 25.BAYER: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 26.BAYER: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 27.GLAXOSMITHKLINE: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 28.GLAXOSMITHKLINE: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 29.GLAXOSMITHKLINE: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 30.J&J: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 31.J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 32.J&J: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 33.NOVARTIS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 34.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 35.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 36.PFIZER: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 37.PFIZER: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 38.PRESTIGE: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 39.PRESTIGE: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 40.PRESTIGE: REVENUE SHARE BY REGION, 2021(%)
  • FIGURE 41.P&G: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 42.P&G: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 43.P&G: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 44.RECKITT: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 45.RECKITT: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 46.SUN PHARMA: NET SALES, 2018-2020 ($MILLION
  • FIGURE 47.SUN PHARMA: REVENUE SHARE BY REGION, 2020 (%)